WO2009020201A1 - 単離された細胞集団 - Google Patents

単離された細胞集団 Download PDF

Info

Publication number
WO2009020201A1
WO2009020201A1 PCT/JP2008/064282 JP2008064282W WO2009020201A1 WO 2009020201 A1 WO2009020201 A1 WO 2009020201A1 JP 2008064282 W JP2008064282 W JP 2008064282W WO 2009020201 A1 WO2009020201 A1 WO 2009020201A1
Authority
WO
WIPO (PCT)
Prior art keywords
tissue
cells
stem cell
excellent ability
cell mass
Prior art date
Application number
PCT/JP2008/064282
Other languages
English (en)
French (fr)
Inventor
Hiromasa Miyaji
Masahiro Ikkaku
Hidetaka Sato
Original Assignee
Kyowa Hakko Kirin Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co., Ltd. filed Critical Kyowa Hakko Kirin Co., Ltd.
Priority to CN200880109220A priority Critical patent/CN101848991A/zh
Priority to JP2009526500A priority patent/JPWO2009020201A1/ja
Priority to EP08792339A priority patent/EP2184349A4/en
Publication of WO2009020201A1 publication Critical patent/WO2009020201A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

　造血幹細胞移植、幹細胞移植を利用した障害組織の修復等において、組織への移行能や生着能に優れた細胞が求められている。 　本発明により、組織への移行能や生着能に優れた細胞集団、該細胞を含有する医薬、該細胞の移植方法が提供される。本発明の細胞は造血幹細胞移植や、幹細胞移植を利用した障害組織の修復等に有用である。
PCT/JP2008/064282 2007-08-08 2008-08-08 単離された細胞集団 WO2009020201A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN200880109220A CN101848991A (zh) 2007-08-08 2008-08-08 分离的细胞群
JP2009526500A JPWO2009020201A1 (ja) 2007-08-08 2008-08-08 単離された細胞集団
EP08792339A EP2184349A4 (en) 2007-08-08 2008-08-08 ISOLATED CELL MASS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007206823 2007-08-08
JP2007-206823 2007-08-08

Publications (1)

Publication Number Publication Date
WO2009020201A1 true WO2009020201A1 (ja) 2009-02-12

Family

ID=40341428

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/064282 WO2009020201A1 (ja) 2007-08-08 2008-08-08 単離された細胞集団

Country Status (6)

Country Link
US (1) US20100303766A1 (ja)
EP (1) EP2184349A4 (ja)
JP (1) JPWO2009020201A1 (ja)
KR (1) KR20100042654A (ja)
CN (1) CN101848991A (ja)
WO (1) WO2009020201A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010089605A1 (en) * 2009-02-06 2010-08-12 Reneuron Limited Treatment of limb ischemia
US9265795B2 (en) 2008-12-05 2016-02-23 Reneuron Limited Cellular compositions for use in therapy
JP2017525340A (ja) * 2014-07-07 2017-09-07 ターガザイム，アイエヌシー． 治療的用途のためのフコシル化細胞の製造および凍結保存
JP2018510615A (ja) * 2015-01-21 2018-04-19 フレッド ハッチンソン キャンサー リサーチ センター 遺伝子治療用ポイントオブケア及び／又はポータブルプラットフォーム

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10813917B2 (en) 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
CN104837492B (zh) 2012-12-07 2018-04-27 糖模拟物有限公司 使用e-选择素拮抗剂动员造血细胞的化合物、组合物和方法
MX2016001247A (es) 2013-07-30 2016-08-17 Musculoskeletal Transplant Foundation Matrices derivadas de tejido suave acelular y metodos para preparar las mismas.
EP3227310B1 (en) 2014-12-03 2019-07-31 GlycoMimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
EP3297694A1 (en) 2015-05-21 2018-03-28 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
CN108350077A (zh) * 2015-11-03 2018-07-31 糖模拟物有限公司 产生单克隆抗体、造血干细胞的方法和组合物以及利用所述抗体和造血干细胞的方法
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
JP2019524791A (ja) 2016-08-08 2019-09-05 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ
US11072625B2 (en) 2016-10-07 2021-07-27 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
EP3596096A1 (en) 2017-03-15 2020-01-22 GlycoMimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
US20200199533A1 (en) * 2017-03-23 2020-06-25 King Abdullah University Of Science And Technology Compositions and methods for preparing cd34neg stem cells for transplant
EP3717013A1 (en) 2017-11-30 2020-10-07 GlycoMimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
EP3750987A4 (en) * 2017-12-28 2021-11-10 Kaneka Corporation CELL POPULATION INCLUDING ADHESIVE STEM CELLS, ITS PRODUCTION PROCESS, AND PHARMACEUTICAL COMPOSITION
EP3732186A1 (en) 2017-12-29 2020-11-04 GlycoMimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
EP3761994A1 (en) 2018-03-05 2021-01-13 GlycoMimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
DE102020127787A1 (de) * 2020-10-22 2022-04-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung eingetragener Verein Verfahren zur Kryokonservierung einer Vielzahl von Zellverbänden aus biologischen Zellen
CN117379392B (zh) * 2023-10-11 2024-09-13 谈高 特异性靶向Treg表达FUT7基因的纳米颗粒及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094619A2 (en) * 2003-04-18 2004-11-04 Lijun Xia Hematopoietic stem cells treated by in vitro fucosylation and methods of use
WO2005017115A2 (en) * 2003-08-11 2005-02-24 Mount Sinai School Of Medicine Of New York University Cord blood-derived hematopoietic progenitor cells
WO2007143204A2 (en) * 2006-06-02 2007-12-13 Sacktein Robert Compositions and methods for modifying cell surface glycans

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094619A2 (en) * 2003-04-18 2004-11-04 Lijun Xia Hematopoietic stem cells treated by in vitro fucosylation and methods of use
WO2005017115A2 (en) * 2003-08-11 2005-02-24 Mount Sinai School Of Medicine Of New York University Cord blood-derived hematopoietic progenitor cells
WO2007143204A2 (en) * 2006-06-02 2007-12-13 Sacktein Robert Compositions and methods for modifying cell surface glycans

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
HISASHI NARIMATSU: "Hito to Fucose Ten'i Koso", TOSA SEIBUTSUGAKU TOSA JOHO HATSUGEN KARA JUSHIN NO MECHANISM MADE, vol. 43, no. 16, 1998, pages 2394 - 2403 *
KIMURA, H. ET AL.: "Distinct substrate specificities of five human alpha-1,3- fucosyltransferases for in vivo synthesis of the sialyl Lewis x and Lewis x epitopes", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 237, no. 1, 1997, pages 131 - 137, XP008131784 *
LIU, F. ET AL.: "Transfection of the c-erbB2/neu gene upregulates the expression of sialyl Lewis X, alphal,3-fucosyltransferase VII, and metastatic potential in a human hepatocarcinoma cell line", EUR. J. BIOCHEM., vol. 268, no. 12, 2001, pages 3501 - 3512, XP002434784 *
MARTIN-SATUE, M. ET AL.: "Overexpression of alpha(1,3)-fucosyltransferase VII is sufficient for the acquisition of lung colonization phenotype in human lung adenocarcinoma HAL-24Luc cells", BR. J. CANCER, vol. 80, no. 8, 1999, pages 1169 - 1174, XP008131776 *
NATSUKA, S. ET AL.: "Molecular cloning of a cDNA encoding a novel human leukocyte alpha-1,3-fucosyltransferase capable of synthesizing the sialyl Lewis x determinant", J. BIOL. CHEM., vol. 269, no. 24, 1994, pages 16789 - 16794, XP002179393 *
RUSTER, B. ET AL.: "Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells", BLOOD, vol. 108, no. 12, 2006, pages 3938 - 3944, XP008131786 *
SASAKI, K. ET AL.: "Expression cloning of a novel alphal,3-fucosyltransferase that is involved in biosynthesis of the sialyl Lewis x carbohydrate determinants in leukocytes", J. BIOL. CHEM., vol. 269, no. 20, 1994, pages 14730 - 14737, XP055353965 *
See also references of EP2184349A4 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9265795B2 (en) 2008-12-05 2016-02-23 Reneuron Limited Cellular compositions for use in therapy
WO2010089605A1 (en) * 2009-02-06 2010-08-12 Reneuron Limited Treatment of limb ischemia
JP2012516884A (ja) * 2009-02-06 2012-07-26 リニューロン・リミテッド 肢虚血の治療
AU2010212147B2 (en) * 2009-02-06 2014-03-20 Reneuron Limited Treatment of limb ischemia
US8932577B2 (en) 2009-02-06 2015-01-13 Reneuron Limited Treatment of limb ischemia
US9410122B2 (en) 2009-02-06 2016-08-09 Reneuron Limited Treatment of limb ischemia
JP2017525340A (ja) * 2014-07-07 2017-09-07 ターガザイム，アイエヌシー． 治療的用途のためのフコシル化細胞の製造および凍結保存
JP2018510615A (ja) * 2015-01-21 2018-04-19 フレッド ハッチンソン キャンサー リサーチ センター 遺伝子治療用ポイントオブケア及び／又はポータブルプラットフォーム

Also Published As

Publication number Publication date
CN101848991A (zh) 2010-09-29
US20100303766A1 (en) 2010-12-02
EP2184349A4 (en) 2011-10-26
JPWO2009020201A1 (ja) 2010-11-04
EP2184349A1 (en) 2010-05-12
KR20100042654A (ko) 2010-04-26

Similar Documents

Publication Publication Date Title
WO2009020201A1 (ja) 単離された細胞集団
WO2008118392A3 (en) Synthetic cell platforms and methods of use thereof
EP2727998A3 (en) Methods for purifying pancreatic endoderm cells derived from human embryonic stem cells
WO2010111409A3 (en) Pluripotent stem cells
WO2009007852A3 (en) Multipotent/pluripotent cells and methods
WO2008005520A3 (en) Temperature-responsive microcarrier
WO2008085221A3 (en) Therapeutic use of cd31 expressing cells
CA2801009C (en) Native wharton's jelly stem cells and their purification
WO2010124142A3 (en) Cell compositions derived from dedifferentiated reprogrammed cells
IL191771A0 (en) Improved composition for collecting and preserving placental stem cells and methods of using the composition
WO2007136424A3 (en) Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates
IL196137A0 (en) Method for stem cell culture and cells derived therefrom
ZA200810412B (en) Placental niche and use thereof to culture stem cells
BRPI0819936A2 (pt) Preparação farmacêutica, método para produzir células dendríticas, células dendríticas, composição farmacêutica, e, uso de uma célula dendrítica ou uma preparação.
EP1983042A4 (en) PROCESS FOR THE PURIFICATION OF CARDIAC MYOCYTES AND PRESOMPTIVE CARDIAC MYOCYTES DERIVED FROM STEM CELLS AND F TUS
WO2008090340A3 (en) Nucleic acid amplification and testing
WO2010033920A3 (en) Compositions and methods for enhancing cell reprogramming
WO2010062911A3 (en) Compositions and methods of functionally enhanced in vitro cell culture system
WO2008148105A8 (en) Endometrial stem cells and methods of making and using same
EP4296270A3 (en) A composition comprising stem cell cultures
WO2009140452A3 (en) Isolation of stem cell precursors and expansion in non-adherent conditions
WO2007130612A3 (en) Method for obtaining and storing multipotent stem cells
WO2007089627A3 (en) Methods and compositions relating to stem cell transplantation
WO2007130642A3 (en) Modulation of nkg2d
WO2007028079A3 (en) Methods of stimulating expansion of hematopoietic stem cells

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880109220.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08792339

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009526500

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107005050

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008792339

Country of ref document: EP